FDA Clears Palatin's IND Application For Phase 2 Study Of Bremelanotide Co-Administered With Tirzepatide For Obesity, The Phase 2 Study Is Expected To Start By Mid-2024, With Topline Data Results By The End Of 2024
美國食品藥品管理局批准了帕拉丁對佈雷美拉諾肽與替西帕肽共同施用治療肥胖症的2期研究的IND申請,該2期研究預計將於2024年中期開始,主要數據結果將於2024年底公佈